Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Compounding Quality Center of Excellence

Compounding Quality Center of Excellence

                        Compounding Quality Center of Excellence | Instructor-Led Trainings
          Compounding Quality Center of Excellence | Self-Guided Online Trainings
          Compounding Quality Center of Excellence | Recorded Webinars
          Compounding Quality Center of Excellence | Annual Conference
          Outsourcing Facilities Annual Study
          Compounding Quality Center of Excellence | Cross-Sector Stakeholder Group Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Human Drug Compounding
          Compounding Quality Center of Excellence
          Outsourcing Facilities Annual StudyCompounding Quality Center of Excellence Outsourcing Facilities Annual Study
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe FDA Compounding Quality Center of Excellence conducts the Compounding Outsourcing Facilities Annual Study to better understand industry perspectives and challenges, as well as dynamics between suppliers and purchasers.

Each study includes:

a survey of outsourcing facilities
	discussions with outsourcing facilities and their stakeholders
	an analysis of existing dataThe study is conducted by a research partner under FDA’s direction. The research partner develops a report of the study results and findings and provides this information to the agency. Data gathered through surveys and discussions are anonymous to FDA.

**Feedback From Outsourcing Facilities**

The annual studies have collected information about areas such as:

Outsourcing facility perceptions of engagement with the FDA
	How current FDA policies affect outsourcing facilities
	Outsourcing facility needs and challenges that can inform FDA’s future policy and programmatic work
	Topics identified by outsourcing facilities as needs for training or additional clarification
	Size, scope, and trends in the outsourcing facility sector
	Outsourcing facility perceptions of quality and implementation of quality practices
	Interactions between outsourcing facilities and various stakeholders (e.g., suppliers of active pharmaceutical ingredients [APIs] and purchasers of outsourcing facility products)**Summaries of the Annual Reports**

**Executive summary, 2021–2022**: The market for drugs produced by outsourcing facility is durable and evolving. The number of registered outsourcing facilities has remained relatively stable since 2019, and the industry shows wide variation in current good manufacturing practice (CGMP) requirements expertise, resources (i.e., human capital, financial) and ability to grow customer bases. Customer need is playing an increasing role in shaping the industry. Visit Areas of Customer Need for Outsourcing Facility Products for highlights of the research findings.

**Executive summary, 2020–2021**: Outsourcing facilities show movement toward stabilization in the number of facilities in the sector, demand for compounded drugs from customers continues and outsourcing facilities continue to improve their understanding of current good manufacturing practice (CGMP) requirements. Financial and regulatory realities continue to shape the industry. Visit State of Outsourcing Facility Sector and Possibilities for the Future for highlights of the research findings.

**Executive summary, 2019–2020**: Outsourcing facilities are adjusting and trying to understand how to balance regulation with profitable and sustainable business models. The facilities need consistent, constructive communication with FDA that is sensitive to their challenges.

**Selected Research Findings and Subsequent FDA Actions**

*Clarifying FDA Quality Practices and Expectations for Outsourcing Facilities*

	*The research results of these studies* indicate that registered outsourcing facilities enter the market with varying levels of experience and knowledge of quality practices and CGMP requirements. Newly established outsourcing facilities might not be familiar with the expectations associated with FDA regulations, such as inspections or other general requirements. In response, FDA:

	Expanded new CGMP training opportunities identified by outsourcing facilities:
		Process Validation
			Aseptic Process Simulation
			Supplier/Contractor Qualification and Management
			Personnel Gowning in Sterile Drug Production
			Quality Management Systems
		Added sessions to the Compounding Quality Center of Excellence annual conference based on indicated areas of need:
		FDA Inspections of Outsourcing Facilities (PDF – 308KB)
			What to Expect on a 503B Inspection (PDF – 408KB)
			Analytical Testing (PDF – 271KB)
			483s Responses and Reinspection (PDF – 445KB)
			Elevating SOPs and Work Aids 3 (PDF – 4.93MB)
			Stability BUDs (PDF – 386KB)
		Hosted a webinar, FDA Inspections of Outsourcing Facilities, which included a Q&A session with the FDA.
	*Increasing Communication Between Outsourcing Facilities and FDA*

	The research results of these studies indicate that outsourcing facilities prefer more two-way communication with the agency. Outsourcing facilities prefer additional avenues for communication rather than relying on FDA inspections, which the facilities view as their primary means of interacting with the agency. In response, FDA:

	launched, in 2022, a cross-sector stakeholder group with representatives from the agency, outsourcing facilities and other stakeholders. This group promotes information sharing related to quality, production and use across the outsourcing facility sector.
		is conducting small group listening sessions for groups of outsourcing facilities with similar operations.
		obtains input from outsourcing facility representatives on potential topics for the annual Compounding Quality Center of Excellence annual conference.**Contact Us**
Email questions or suggestions to CompoundingQualityCoE@fda.hhs.gov

                                                                                  Content current as of:
      01/26/2024
              
              
Regulated Product(s)
		 DrugsCompounding Quality Center of Excellence

          
                        Instructor-Led Trainings
          Self-Guided Online Trainings
          Webinars
          Annual Conference
          Annual Study
          Cross-Sector Stakeholder Group
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop